IPCALAB

Ipca Laboratories Ltd.

NSE: IPCALAB

BSE: 524494

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,951.00-8.1 (-0.41%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

92.2 / 100

Value Score

25.2 / 100

Price Momentum Score

87.9 / 100

QVM Score

86.7 / 100

Key Metrics

Market Cap

49497.70

P/E (TTM)

37.79

P/B

6.14

P/S (TTM)

4.89

EV/EBITDA

22.01

CAPE (5Y)

65.50

ROE (TTM)

15.20

ROCE (TTM)

16.18

ROA (TTM)

9.46

Avg 3Y ROE

11.77

Earnings 3Y CAGR

38.68

Sales 3Y CAGR

17.47

Sales 5Y CAGR

13.18

Debt/Equity

0.10

Consensus TP

2003.50

Strong Buy %

43.75

Promoter Holding

44.72

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Ipca Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 87.9 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

87.9 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 6.91% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and improving ROE

The company reported strong ROE of 15.2% for 12-month ended 30 Jun 2026 and ROE improved by 409 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 17.8% for 12-month ended 30 Jun 2026 and operating margin improved by 304 bps from 1 year ago

What is Operating profit margin?

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 68.2% for 12-month ended 30 Jun 2026 and the growth was 61.0 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.1 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.1 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 9 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 37.79 indicates that the stock is expensive on a standalone basis and is at a 18.91% premium to industry median P/E

What is P/E Ratio?

Median: 31.78

Value 37.79

-0.96721.13

Low dividend yield

The company has a low dividend yield of 0.31%

What is Dividend yield?

Neutral

Moderate revenue growth and in line with median growth of industry

The company delivered moderate revenue growth of 10.59% for 12-month ended 30 Jun 2026 and the growth was 0.0 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 10.59

-99.6111701.8

Company's earnings are of moderate quality

Earnings quality score of 65.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

65.9 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Ipca Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Ipca Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Ipca Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	46.07	46.07	46.07	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.30	46.30	46.30	44.72	44.72	44.72	44.72	44.72	44.72	44.72
Indian Promoter	46.07	46.07	46.07	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.29	46.30	46.30	46.30	44.72	44.72	44.72	44.72	44.72	44.72	44.72
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	39.37	40.61	41.33	42.72	42.57	43.15	43.92	42.60	43.96	44.34	44.35	44.49	44.64	45.23	44.91	44.79	44.88	44.63	45.05	46.74	46.82	46.87	47.20	47.95	48.08	48.10
Mutual Funds / UTI	23.14	22.82	23.53	20.58	20.85	21.49	21.82	26.05	28.20	29.41	29.71	29.79	29.94	30.27	30.23	29.25	28.83	28.52	28.55	29.63	29.63	29.61	30.04	30.52	31.24	31.15
FI/Bank/Insurance	2.26	4.26	4.25	3.23	3.64	3.36	3.18	3.68	4.20	3.90	3.57	3.76	3.61	4.27	4.12	4.54	4.68	4.64	4.87	5.19	5.64	5.83	5.99	6.15	5.34	5.24
Govt	0.12	0.16	0.28	0.28	0.28	0.22	0.22	0.24	0.24	0.24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	12.64	12.39	12.40	18.22	17.47	17.81	18.46	12.34	11.02	10.61	10.57	10.46	10.58	10.05	9.86	10.27	10.51	10.85	10.83	11.06	10.75	10.67	10.42	10.63	10.63	10.72
Other Institutions	1.20	0.98	0.86	0.41	0.33	0.26	0.24	0.29	0.29	0.19	0.50	0.48	0.51	0.64	0.69	0.72	0.86	0.62	0.80	0.86	0.78	0.76	0.74	0.65	0.87	0.97
Non-Institution	14.56	13.32	12.59	10.99	11.14	10.57	9.80	11.11	9.75	9.37	9.35	9.22	9.07	8.47	8.81	8.92	8.82	9.07	8.65	8.53	8.46	8.41	8.08	7.33	7.20	7.18
Bodies Corporate	1.91	0.99	1.15	0.59	0.75	0.75	0.72	1.17	0.50	0.51	0.47	0.45	0.44	0.34	0.42	0.47	0.43	0.57	0.47	0.45	0.47	0.42	0.37	0.34	0.33	0.34
Others (incl. Retail) No. of shareholders	12.65 79,559	12.33 91,828	11.44 1,01,410	10.40 99,941	10.39 99,204	9.82 1,04,113	9.08 93,914	9.94 1,05,720	9.25 1,14,338	8.86 1,09,883	8.88 1,10,077	8.77 1,07,283	8.63 1,09,049	8.13 99,221	8.39 95,233	8.45 82,147	8.39 80,420	8.50 83,941	8.18 82,170	8.08 89,344	7.99 87,440	7.99 84,773	7.71 82,129	6.99 76,989	6.87 81,447	6.84 81,261

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Pharma	2.46%	14 / 20
2	Nifty Healthcare	2.11%	17 / 20
3	Nifty Midcap 150	0.58%	73 / 149
4	NIFTY Large Midcap 250	0.29%	122 / 250
5	Nifty 500	0.12%	170 / 499
6	Nifty Total Market	0.12%	174 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Ipca Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
MANISH KUMAR JAIN Designated Person	February-2026	Market Sale (Disposal) 18th Feb 2026	0.01 %	₹ 1,482.22	3.00 k	₹ 44.47 lac
Pawan Kothari Designated Person	August-2025	Market Sale (Disposal) 25th Aug 2025	0.00 %	₹ 1,413.02	2.22 k	₹ 31.37 lac
Mrs. Usha M. Chandurkar Promoter Group	December-2024	Market Sale (Disposal) 19th Dec 2024	3.27 %	₹ 1,499.25	40.00 lac	₹ 599.70 cr
Paschim Chemicals Pvt. Ltd. Promoter Group	March-2024	Market Purchase (Acquisition) 12th Mar 2024	4.00 %	₹ 1,200.97	35.00 k	₹ 4.20 cr
Mr. Ajit Kumar Jain Director	November-2023	Market Sale (Disposal) 20th Nov 2023	0.02 %	₹ 1,081.85	20.00 k	₹ 2.16 cr
Mr. E. J. Babu Former Designated Employee Other	September-2022	Market Sale (Disposal) 19th Sep 2022	0.01 %	₹ 874.39	2.00 k	₹ 17.49 lac
Mr. A. K. Jain Director	March-2022	Market Sale (Disposal) 21st Mar 2022	0.03 %	₹ 1,026.82	20.00 k	₹ 2.05 cr
Kavita Sehwani Designated Person	August-2021	Market Sale (Disposal) 26th Aug 2021	0.02 %	₹ 2,441.16	450.00	₹ 10.99 lac
Pabitra Kumar Bhattacharyya Designated Person	August-2021	Market Sale (Disposal) 23rd Aug 2021	0.00 %	₹ 2,510.00	4.00 k	₹ 1.00 cr
Ajit Kumar Jain Director	August-2021	Market Sale (Disposal) 19th Aug 2021	0.04 %	₹ 2,421.90	10.00 k	₹ 2.42 cr

Corporate Actions

History of Ipca Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 6/share
Record date: 7th Aug 2026Ex-date: 7th Aug 2026
Announced on: 29th May 2026
Dividend₹ 2/share
Record date: 5th Aug 2025Ex-date: 5th Aug 2025
Announced on: 29th May 2025
Dividend₹ 2/share
Record date: 27th Nov 2024Ex-date: 27th Nov 2024
Announced on: 24th Oct 2024
Dividend₹ 2/share
Record date: 6th Aug 2024Ex-date: 6th Aug 2024
Announced on: 29th May 2024
Dividend₹ 2/share
Record date: 22nd Nov 2023Ex-date: 22nd Nov 2023
Announced on: 25th Oct 2023

Company Profile

Overview of Ipca Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquin...

Key personnel

Mr. Pabitra Kumar Bhattacharya

President - Operations (API)

Mr. Sunil Ghai

President - Marketing

Dr. Sanjay U. Kapadia

President - Corporate Quality Assurance

Dr. Ashok Kumar

President - Research and Development (Chemicals)

Mr. Shailesh Laul

President - Operations (Formulations)

Mr. Hitesh Kumar Maheshwari

President - Research and Development (Formulations)

Mr. Shashil Mendonsa

President - International Marketing

Saidutta Nanda

President - HR

View all

Incorporated on

19 Oct 1949

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

17,210

IPO date

23 Feb 1994

Free Float

13,93,91,349

Website

https://www.ipca.com/

Phone no.

+912262105000

Address

125, Kandivli Industrial Estate, Kandivli (West),, MUMBAI, 400067, India

Frequently Asked Questions

What is the current share price of Ipca Laboratories Ltd.?

The current share price of Ipca Laboratories Ltd. is ₹ 1,951.00 as of 8 Sep 2026.

What is the market capitalisation of Ipca Laboratories Ltd.?

The market capitalisation of Ipca Laboratories Ltd. stands at ₹ 49,497.70 Cr.

What is the PE ratio of Ipca Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd. is 37.79 as of the latest trailing twelve months data.

What is the ROE and ROCE of Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. has a Return on Equity (ROE) of 15.20% and a Return on Capital Employed (ROCE) of 16.18% as per the latest financial reports.

What is the 52-week high and low of Ipca Laboratories Ltd.?

The 52-week high of Ipca Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Ipca Laboratories Ltd.?

The dividend yield of Ipca Laboratories Ltd. is 0.31% based on the current market price.

What is the FII and DII holding in Ipca Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 10.72%, Domestic Institutional Investors (DII) hold 36.39% and retail/public investors hold 6.84% of Ipca Laboratories Ltd. shares.

What sector does Ipca Laboratories Ltd. belong to?

Ipca Laboratories Ltd. operates in the Healthcare sector. 75% of analysts have a Buy or Strong Buy rating on Ipca Laboratories Ltd. with a consensus target price of ₹ 2,003.50, implying 2.69% upside from current levels.

What is the beta of Ipca Laboratories Ltd.?

The beta of Ipca Laboratories Ltd. is 0.09, indicating its price volatility relative to the broader market. Over the past 1 year, Ipca Laboratories Ltd. has delivered an absolute return of 42.63%.

What is the RSI of Ipca Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Ipca Laboratories Ltd. is 61.89, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Ipca Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Ipca Laboratories Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Company Profile

Corporate Actions